Skip to content

Comparison of Analgesic Effects Between Perineural Liposomal Bupivacaine Infiltration and the Combined Adductor Canal Block (ACB) with iPACK Block for Postoperative Pain Management in Total Knee Arthroplasty

Comparison of Analgesic Effects Between Perineural Liposomal Bupivacaine Infiltration and the Combined Adductor Canal Block (ACB) with iPACK Block for Postoperative Pain Management in Total Knee Arthroplasty

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105943
Enrollment
Unknown
Registered
2025-07-15
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Knee Arthroplasty (TKA)

Interventions

ACB+iPACK group:One hour preoperatively, an anesthesiologist performed ultrasound-guided ACB and iPACK blocks using 266 mg of liposomal bupivacaine diluted in 20 mL of 0.9% normal saline to prepare a
PAI group:Patients underwent the same ultrasound-guided needle insertion procedure as the ACB+iPACK group, with the needle tip advanced to the target anatomical location. A 2-mL test dose of normal sa

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-79 years; 2. Scheduled for unilateral total knee arthroplasty (TKA); 3. ASA physical status classification I-III; 4. Body mass index (BMI) ranging from 18 to 35 kg/m².

Exclusion criteria

Exclusion criteria: 1. Severe valgus deformity or flexion contracture requiring complex knee arthroplasty or revision surgery with operative time >3 hours; 2. Diabetes mellitus; 3. History of psychiatric or neurological disorders that may interfere with pain assessment; 4. Prolonged QT interval; 5. Chronic use of opioids or gabapentinoids; 6. Severe cardiac, hepatic, or renal dysfunction; 7. Coagulation disorders; 8. Infection at the puncture site; 9. History of allergy to liposomal bupivacaine; 10. Epilepsy; 11. Alcohol abuse; 12. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale (VAS) pain scores at rest and with the knee flexed to 45 degrees postoperatively;

Secondary

MeasureTime frame
Time to first postoperative rescue analgesia;Cumulative opioid consumption within 72 hours postoperatively;Maximum knee flexion angle on postoperative days 1, 2, and 3 (POD1, POD2, POD3);Time to first ambulation after surgery;Quadriceps muscle strength scores on postoperative days 1, 2, and 3 (POD1, POD2, POD3);Common peroneal nerve (CPN) sensory and motor function assessments on postoperative days 1, 2, and 3 (POD1, POD2, POD3);Tibial nerve sensory and motor function assessments on postoperative days 1, 2, and 3 (POD1, POD2, POD3);Incidence of posterior knee pain;PainOUT questionnaire scores on postoperative days 1, 2, and 3 (POD1, POD2, POD3);Time to first oral intake after surgery;Postoperative hospital stay;

Countries

China

Contacts

Public ContactPeipei Peng

The First Affiliated Hospital of Nanjing Medical University

617753646@qq.com+86 137 7660 1502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026